CURRENTLast verified 2026-10-07

Biological products: registration and re-registration file content — Egypt

Country: Egypt
Official organization: Egyptian Drug Authority (EDA)
Category: regulatory intelligence
Product / sector: Biological Products
Publication / issue date: 2026-05-25
Document version: 05
Official source: Guideline for file content of biological products submitted for registration and re-registration file

OFFICIAL SOURCE FACTS / REQUIREMENT FRAMEWORK

What you need to know

EDA version 05 specifies Egypt-specific administrative and regulatory information for Module 1 of biological-product submissions.
It distinguishes that regional information from CTD Modules 2–5.

This summary is not a complete regulatory checklist. Applicability, conditions and exclusions remain governed by the original official document.

Who is affected

Biological-product manufacturers
Marketing Authorization Holders
Regulatory Affairs teams

PHARMA GATE INTERPRETATION — NOT AN OFFICIAL REQUIREMENT

Pharma Gate Intelligence

Use the applicable registration or re-registration requirements rather than treating all CTD information as interchangeable.

Business impact

The regional submission package needs its own readiness review.

RECOMMENDED ACTION — NOT A REGULATORY DETERMINATION

What to check

Registration versus re-registration scope
Module 1 and relevant annexes
Product-specific administrative evidence

Recommended next step

Map the proposed submission against the current official file-content guideline.

Biological product
Submission type
Regional dossier requirements
Gap review
Regulatory support

NEXT STEP

Need help navigating this requirement?

Pharma Gate is not a regulatory authority. Professional providers are independent organizations subject to platform review.

VERIFIED SOURCE GOVERNANCE

Official facts are attributed to issuing authorities. Pharma Gate analysis and recommended actions are clearly separated.

How we verify intelligence

Official facts are attributed to the issuing organization. Pharma Gate interpretation and recommended actions are separate editorial layers, not legal requirements or regulatory approval. Sources are prioritized: national regulators, WHO and recognized intergovernmental bodies, official procurement organizations, then other official governmental or institutional sources.

Publication records retain source title, version, issue date, verification date, country, sector and status. Draft / Public Consultation is distinct from Current. Superseded and Archived records do not represent current requirements. A verification date records the review performed; it is not an assurance of continuous monitoring. Always check the latest official source before acting.